Neurocrine partnership update: Neurocrine has stated that, pending successful FDA IND clearance, it intends to initiate a clinical trial with NBIB-‘223 for Friedreich’s ataxia in H2 2026.
Tuesday, March 10, 2026
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
March 09, 2026 16:01 ET | Source: Voyager Therapeutics, Inc..
